This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Centene Corporation is a well-diversified, multi-national healthcare company that primarily provides a set of services to the government sponsored healthcare programs. The company serves the under-insured and uninsured individuals through member-focused services. It is also engaged in providing education and outreach programs to inform and assist members in accessing quality, appropriate healthcare services. Centene is now a $100-billion plus enterprise catering healthcare services to more than 24 million members across 50 states. The recent acquisition of WellCare Health leveraged the company’s position as the largest Medicaid managed care organization in the country. The combined entity now has 22 million members. In 2019, the company retained its market-leading position nationwide, serving 1.8 million exchange members across 20 states at the year-end.
Compelling Reasons for Investors to Hold on to Centene Stock
by Zacks Equity Research
CNC remains well-poised for growth on the back of an expanding customer base, improved premiums, strategic acquisitions and commendable cash reserves.
SEM Plunges 48.2% in 6 Months: Should You Buy, Hold or Sell the Stock?
by Zacks Equity Research
Rising expenses and high leverage are impacting Select Medical's prospects.
UnitedHealth Stock Down 15.9% in 3 Months: Should You Hold or Fold?
by Zubia Masood
UNH faces challenges such as rising medical costs and regulatory pressures. However, it boasts robust cash flow and consistent dividend growth.
Centene Unveils Its 2025 Guidance, Reaffirms 2024 Outlook
by Zacks Equity Research
CNC expects robust growth in its Medicaid, Marketplace and Medicare businesses. This is likely to be driven by rate increases, rising uninsured individuals and dual expansions.
Rising Costs, Denied Claims and a Tragedy: Health Insurers Stumble
by Kaibalya Pravo Dey
Shares of UnitedHealth, Centene, Elevance Health and CVS Health have witnessed significant declines since last Wednesday.
UnitedHealth 2025 Outlook Clouded by Heartbreaking Loss of Key Leader
by Zacks Equity Research
UNH expects 2025 operating cash flows to be within $32-$33 billion.
Recalculation Ahead: Implications of UnitedHealth's Win Against CMS
by Kaibalya Pravo Dey
UNH's success marks the third recent defeat for CMS in star ratings lawsuits, raising hopes for Humana and Centene as they challenge their own ratings.
3 Stocks Seeing Insider Buys: CNC, PFE, BMY
by Derek Lewis
Investors can see insider buys as an overall net positive concerning the longer-term outlook for a stock.
Acadia Healthcare Shares Down 18.7% Despite Q3 Earnings Beat
by Zacks Equity Research
ACHC's better-than-expected third-quarter earnings benefit from higher patient days and improving volumes. Closing two facilities led the company to reduce its 2024 revenue guidance.
Select Medical Up 13.8% Since Q3 Earnings Top on Patient Day Growth
by Zacks Equity Research
SEM's strong third-quarter results benefit from improving patient days and admissions in the Rehabilitation Hospital segment. Elevated expenses partially offset the positives.
Tenet Q3 Earnings Beat on Strong Ambulatory Unit, '24 EPS View Raised
by Zacks Equity Research
THC's Q3 results benefit from higher same-hospital admissions and Medicaid supplemental revenue gains. Cost-cutting measures help offset challenges from hospital divestitures.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Company News for Oct 28, 2024
by Zacks Equity Research
Companies In The Article Are: CPRI, TPR, CNC, SNY,AON
Centene Q3 Earnings Beat on Growth in Marketplace Business Line
by Zacks Equity Research
CNC's Q3 results benefit from growth in premiums, driven by strong product positioning. Despite higher revenues, declines in Medicaid membership and increased expenses weigh on profitability.
Durable Orders More or Less in Line With Expectations
by Zacks Equity Research
Durable Orders More or Less in Line With Expectations.
Holding Pattern Continues; CNC, BAH Post Big Beats
by Mark Vickery
We don't expect much directional impetus in the stock market until after the presidential election is decided.
Centene (CNC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Centene (CNC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Centene (CNC) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of 16.55% and 10.86%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy or Sell Centene Stock Before Q3 Earnings Report?
by Zacks Equity Research
CNC's third-quarter earnings are likely to have been affected by lower premiums and rising medical costs.
Analysts Estimate Humana (HUM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Humana (HUM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Unveiling Centene (CNC) Q3 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Centene (CNC) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Should You Buy or Hold Molina Healthcare Stock Before Q3 Earnings?
by Zacks Equity Research
MOH's third-quarter earnings are likely to have benefited from growing premiums, partially offset by higher expenses.
Earnings Preview: Centene (CNC) Q3 Earnings Expected to Decline
by Zacks Equity Research
Centene (CNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Centene's Meridian Unit Wins Michigan Contract for HIDE SNP Plan
by Zacks Equity Research
CNC's Meridian subsidiary secures a contract to provide integrated Medicare and Medicaid services in Michigan through a new HIDE SNP program, which is expected to boost its member base and statewide presence.
5 Broker-Friendly Stocks Worth Watching Currently
by Maharathi Basu
Investors should monitor stocks like American Airlines, Alaska Air, Delta, Warner Bros. and Centene for high returns.